NasdaqCM - Nasdaq Real Time Price USD

Genenta Science S.p.A. (GNTA)

2.5900 -0.3400 (-11.60%)
At close: April 26 at 4:00 PM EDT
2.3500 -0.24 (-9.27%)
After hours: April 26 at 5:02 PM EDT

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Pierluigi Paracchi Vice Chairman of the Board, CEO & GM -- -- 1973
Dr. Luigi Naldini M.D., Ph.D. Co-Founder & Chairman of the Executive Scientific Board -- -- 1959
Dr. Bernard Rudolph Gentner M.D., Ph.D. Co-Founder & Member of the Executive Scientific Board -- -- 1975
Mr. Richard B. Slansky Chief Financial Officer -- -- 1958
Dr. Carlo Russo M.D. Chief Medical Officer & Head of Development -- -- 1953
Dr. Stefania Mazzoleni Ph.D. Director of Program Development -- -- 1982
Ms. Barbara Regonini Director of Finance -- -- 1973

Genenta Science S.p.A.

Via Olgettina No. 58
Milan, MI 20132
Italy
https://www.genenta.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
14

Description

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Corporate Governance

Genenta Science S.p.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Apr 08, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 01, 2024
    20-F/A: Periodic Financial Reports
    See Full Filing
  • Mar 29, 2024
    20-F: Periodic Financial Reports
    See Full Filing
  • Oct 20, 2023
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • May 22, 2023
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing

Upcoming Events

Related Tickers

TELO Telomir Pharmaceuticals, Inc.
6.87
+1.85%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%
 
ENZN Enzon Pharmaceuticals, Inc.
0.0835
-5.17%
 
PTIX Protagenic Therapeutics, Inc.
1.3850
-4.48%
 
NP5.F Newron Pharmaceuticals S.p.A.
6.92
-0.14%
 
CHRO Chromocell Therapeutics Corporation
1.6000
+6.67%
 
YDO1.F Madrigal Pharmaceuticals, Inc.
179.30
-0.25%
 
MVIR.ST Medivir AB (publ)
3.2400
+6.23%
 
CVKD Cadrenal Therapeutics, Inc.
0.4305
+1.63%
 
RAD.AX Radiopharm Theranostics Limited
0.0460
+2.22%